Details for Patent: 10,441,194
✉ Email this page to a colleague
Which drugs does patent 10,441,194 protect, and when does it expire?
Patent 10,441,194 protects ABILIFY MYCITE KIT and is included in one NDA.
This patent has twenty-one patent family members in thirteen countries.
Summary for Patent: 10,441,194
Title: | Ingestible event marker systems |
Abstract: | Ingestible event marker systems that include an ingestible event marker (i.e., an IEM) and a personal signal receiver are provided. Embodiments of the IEM include an identifier, which may or may not be present in a physiologically acceptable carrier. The identifier is characterized by being activated upon contact with a target internal physiological site of a body, such as digestive tract internal target site. The personal signal receiver is configured to be associated with a physiological location, e.g., inside of or on the body, and to receive a signal the IEM. During use, the IEM broadcasts a signal which is received by the personal signal receiver. |
Inventor(s): | Robertson; Timothy (Belmont, CA), Savage; George (Portola Valley, CA), Zdeblick; Mark (Portola Valley, CA), Behzadi; Yashar (Anaheim, CA), Costello; Benedict (Piedmont, CA), Frank; Jeremy (San Francisco, CA), Hafezi; Hooman (Redwood City, CA), Haniff; Tariq (Redwood City, CA), O'Reilly; David (Palo Alto, CA) |
Assignee: | PROTEUS DIGITAL HEAL TH, INC. (Redwood City, CA) |
Application Number: | 14/341,636 |
Patent Claim Types: see list of patent claims | Use; Composition; |
Drugs Protected by US Patent 10,441,194
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Otsuka | ABILIFY MYCITE KIT | aripiprazole | TABLET;ORAL | 207202-001 | Nov 13, 2017 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | ||||
Otsuka | ABILIFY MYCITE KIT | aripiprazole | TABLET;ORAL | 207202-002 | Nov 13, 2017 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | ||||
Otsuka | ABILIFY MYCITE KIT | aripiprazole | TABLET;ORAL | 207202-003 | Nov 13, 2017 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | ||||
Otsuka | ABILIFY MYCITE KIT | aripiprazole | TABLET;ORAL | 207202-004 | Nov 13, 2017 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | ||||
Otsuka | ABILIFY MYCITE KIT | aripiprazole | TABLET;ORAL | 207202-005 | Nov 13, 2017 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 10,441,194
Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
---|---|---|---|---|---|
Australia | 2008210291 | ⤷ Try a Trial | |||
Canada | 2676407 | ⤷ Try a Trial | |||
China | 101686800 | ⤷ Try a Trial | |||
Denmark | 3785599 | ⤷ Try a Trial | |||
European Patent Office | 2107883 | ⤷ Try a Trial | |||
>Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |